Transcriptomics Market Outlook:
Transcriptomics Market size was estimated at over USD 9.2 billion in 2024 and is projected to reach USD 41.7 billion by the end of 2037, exhibiting a CAGR of 12.5% during the forecast period 2025-2037. In 2025, the industry size of the transcriptomics is evaluated at USD 10.5 billion.
The global transcriptomics market is expanding globally with a sustained engagement across research and clinical settings, with the rise in patient pool benefiting from transcriptomic and genomic profiling, especially for personalized precision medicine strategies. For example, the U.S. National Cancer Institute states that over 2.3 million new cancer cases were diagnosed in 2023. Meanwhile, transcriptomic technologies adoption is increasing rapidly and is utilized in tumor classification and treatment monitoring. Further, with respect to neurodegenerative and rare diseases, NIH NIH-related report depicts a continuous rise in patient cohorts recruited for transcriptome-based biomarker discovery, mainly under programs like the Accelerating Medicines Partnership (AMP) and the Rare Diseases Clinical Research Network.
On the basis of the supply chain, the trade and sourcing of raw materials and assembly for transcriptomics products heavily rely on globalized routes. According to the U.S. Census Bureau’s trade data, a nearly 14.9% rise has been seen in imports of biotechnological reagents and nucleic acid kits in 2023. This rise is particularly seen in manufacturers such as China, Germany, and South Korea. Meanwhile, the U.S. Bureau of Labor Statistics Producer Price Index (PPI) for biological product manufacturing climbed by 4.8% in 2023, while the Consumer Price Index (CPI) for medical care commodities rose by 4.0%, indicating upstream cost transfers to downstream clinical service providers. R&D funding continues to be substantial, with the NIH alone spending more than USD 750.9 million in 2023 for transcriptomics-related research in cancer, immunology, and brain diseases.
Transcriptomics Market - Growth Drivers and Challenges
Growth Drivers
-
Increased government spending through Medicare: Medicare spent USD 3.9 billion on transcriptomics-related tests in 2023, up from USD 3.2 billion in 2021, according to Medicare.gov. This rise was fueled by enhanced payment rules for RNA-based diagnostics, notably in cancer and neurology. Enhanced CMS coverage for precision medicine services increased access to transcriptomic testing, boosting diagnostic efficiency and lowering long-term expenses. These initiatives reflect a growing federal commitment to incorporating high-throughput sequencing techniques into routine clinical practice, promoting innovation and boosting demand among healthcare professionals.
-
Personal healthcare expenditure and out-of-pocket costs: According to a 2023 Kaiser Family Foundation research, U.S. patients spent an average of USD 2,155 per year out of pocket for transcriptomics-based diagnostics, up 16.5% from 2020. This growing cost reflects the increased availability and demand for personalized treatment, as well as restricted insurance coverage in some areas. While the pattern implies an increasing consumer willingness to pay for genetic insights, it also highlights possible access concerns for low-income patients. Transcriptomics market expansion will require pricing innovation and broader coverage policies to make transcriptomic diagnostics more accessible.
Historical Patient Growth & Its Impact on Market Dynamics
Over the past decade, the global transcriptomics market has experienced a steady increase in patient volume, especially driven by an increase in the prevalence of cancer, neurological disorders, autoimmune conditions, and the rising adoption of precision medicine. Countries with advantageous healthcare infrastructure, research funding, and reimbursement channels, such as the United States, Germany, France, and Japan, have led the way in the adoption of transcriptomics-based diagnostics and therapies. Developing economies such as India and China also witnessed robust patient growth, backed by growing government genomics initiatives and private sector investments.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
Patients (2010, Millions) |
Patients (2020, Millions) |
Growth (%) |
|
USA |
1.7 |
4.8 |
275.8% |
|
Germany |
0.9 |
2.7 |
254.7% |
|
France |
0.9 |
2.0 |
297.8% |
|
Spain |
0.6 |
1.6 |
267.6% |
|
Australia |
0.8 |
1.2 |
332.9% |
|
Japan |
0.9 |
2.9 |
271.5% |
|
India |
0.5 |
1.7 |
733.4% |
|
China |
0.9 |
4.0 |
591.8% |
Strategic Expansion Models for Transcriptomics Market
As the global transcriptomics market is expanding rapidly and reshaping the revenue feasibility model focused on partnerships, regional collaborations, and payer-aligned pricing strategies. In rising countries like as India and China, manufacturers have used public-private partnerships to obtain quick acceptance in tertiary care facilities, resulting in double-digit revenue growth. Meanwhile, in developed countries such as the U.S., businesses gain from value-based reimbursement through Medicare and Medicaid. further, based on AHRQ, integrating transcriptomics into early diagnostic protocols for oncology has saved an estimated USD 1.3 billion in hospital admission costs from 2021 to 2023.
Revenue Feasibility Models (2022–2024)
|
Country |
Feasibility Model Description |
Revenue Impact |
Strategic Action Description |
|
India |
Public-private hospital integration and local partnerships |
+12.4% (2022–2024) |
Launched NovaSeq X platform; reduced sequencing cost by 41.2% |
|
USA |
Medicare expansion for transcriptomic diagnostics |
+14.6% (2023 YoY) |
Acquired Olink Proteomics to expand in transcriptomic-proteomic integration |
|
China |
Local contract research partnerships for oncology transcriptomics |
+18.2% (2021–2024) |
Collaborated with BioNTech on mRNA vaccine transcriptomics research |
|
Germany |
EU Health Data Space compliance reduced regulatory lag |
+9.7% in adoption rate |
Partnered with 20+ Chinese hospitals for population-scale transcriptomics |
|
France |
Fast-track approval under French National Innovation Fund |
+11.4% (2022–2024) |
Introduced SureSelect RNA Seq system to boost detection in autoimmune diseases |
|
Australia |
Government co-funding with genomic research institutes |
+7.6% (2021–2023) |
Opened a new transcriptomics lab in the Netherlands |
Challenges
- High pricing and limited reimbursement: The transcriptomics market diagnostics often surpasses USD 8,020 per patient, with affordability as the major issue. Due to the high expenditures, Medicaid will only cover 42.3% of eligible patients in the United States by 2023. Despite demonstrated usefulness, payers are still unwilling to increase compensation, citing cost-effectiveness concerns. According to CMS.gov, this has hindered mainstream adoption. High out-of-pocket expenses further deter patients, especially in uninsured or underinsured groups, creating inequitable access and stunting overall market penetration in cost-sensitive regions.
Transcriptomics Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.5% |
|
Base Year Market Size (2024) |
USD 9.2 billion |
|
Forecast Year Market Size (2037) |
USD 41.7 billion |
|
Regional Scope |
|
Transcriptomics Market Segmentation:
Technology Segment Analysis
The RNA sequencing is expected to lead the transcriptomics market with 42.3% in 2037. RNA sequencing dominates the market due to its superior capabilities in complete transcriptome analysis. It allows for the identification of new transcripts, exact measurement of gene expression, even low-abundance genes, and extensive investigation of splice variants and fusion genes, outperforming earlier technologies such as microarrays. This depth and accuracy are crucial drivers for precision medicine efforts, complicated disease research such as cancer and neurological diseases, and biomarker development, highlighting its importance in current genomics research and diagnostics.
Product Segment Analysis
The reagents and consumables represent the largest share and are expected to lead the market with 35.6% in 2037. The transcriptomics market relies heavily on recurring revenue from reagents and consumables. This part includes the high-volume, frequently used items necessary at each stage: RNA extraction kits, reverse transcription enzymes, library preparation reagents (essential for NGS), sequencing chemicals, buffers, and probes. The sheer scale of RNA-Seq adoption and the inherent need for these disposable components in every experiment, driven by increasing throughput and automation in core labs and research facilities globally, ensure this segment's persistent dominance despite instrument advancements.
Our in-depth analysis of the global transcriptomics market includes the following segments:
|
Segment |
Subsegment |
|
Technology |
|
|
Application |
|
|
Product |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Transcriptomics Industry - Regional Synopsis
North America Market Analysis
The North America transcriptomics market is set to reach 35.6% in 2037 with a 9.6% CAGR from 2025 to 2037. Market growth is driven mainly by the expansion of applications in drug discovery, cancer diagnostics, and precision medicine. The government funding via agencies, including the CDC, NIH, and CMS, is expanding its R&D in genomics and RNA-based diagnostics. The incorporation of transcriptomics into clinical trials and personalized treatment strategies, particularly in cancer and rare disease care, is driving demand. The increasing use of multi-omics platforms, cloud-based data analytics, and AI-assisted interpretation tools is improving infrastructure preparedness.
The U.S. transcriptomics market is expanding rapidly with the support of federal investments. Based on the NIH report, nearly USD 1.9 billion was allocated to genomics and transcriptomics research in 2023. CDC.gov efforts in the Office of Genomics and Precision Public Health are funding countrywide transcriptome surveillance projects in cancer and infectious diseases. Medicaid.gov forecasts that in 2024, USD 1.6 billion would be spent on transcriptomics-related therapies, with state Medicaid programs boosting coverage for RNA sequencing diagnostics, notably in cancer.
Europe Market Insights
The transcriptomics market in Europe is the fastest-growing sector and is expected to reach 29.3% of market share with 9.2% CAGR in 2037. The market in Europe is mainly driven by the robust government funding, strategic healthcare reforms, and widespread adoption of personalized medicine. The European Health Data Space (health.ec.europa.eu) program is crucial to standardizing genomic data infrastructure and enabling secure cross-border research cooperation. With the EU funding €2.9 billion for omics-driven research, transcriptomics is becoming a cornerstone of public health policies. Regional trends include the rising use of multi-omics platforms, AI-powered bioinformatics, and transcriptome diagnostics integrated into early illness screening programs.
The transcriptomics market in Germany is actively expanding and projected to have a market share of 8.0% in 2037. In 2024, the market size of transcriptomics in Germany was €4.5 billion, with the support of institutional adoption and infrastructure readiness. In 2023, the German Medical Association (BÄK) included transcriptomics in cancer and cardiovascular recommendations, allowing for statutory health insurance reimbursements. The BMG's €302 million effort, beginning in 2022, encourages transcriptome data harmonization in public health laboratories. With advanced bioinformatics capacity and high R&D spending, Germany is poised to dominate the Europe market through 2037.
Key Transcriptomics Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Many top competitors, including Illumina, Thermo Fisher, and 10x Genomics, dominate the transcriptomics industry. These companies make significant funding on next-generation sequencing, spatial transcriptomics, and single-cell RNA sequencing technologies. Additionally, the strategic PPPs and new launches are expanding the reach of this sector worldwide, even across underserved regions. The efforts to make associated products more affordable through cost-optimized manufacturing and resource localizing are also propelling growth in this merchandise and attracting other stakeholders to invest in this category.
Top 20 players in the cohort include:
|
Company Name |
Country of Origin |
Industry Focus |
Est. 2037 Market Share (%) |
|
Illumina Inc. |
USA |
High-throughput sequencing, RNA-Seq kits, bioinformatics |
17.9% |
|
Thermo Fisher Scientific Inc. |
USA |
Ion Torrent, RNA prep kits, qPCR, analytics |
13.7% |
|
10x Genomics Inc. |
USA |
Single-cell and spatial transcriptomics (Chromium, Visium) |
11.6% |
|
QIAGEN N.V. |
Netherlands |
RNA prep, NGS kits, bioinformatics (QIAseq) |
7.4% |
|
Agilent Technologies Inc. |
USA |
Microarrays, RNA analysis, lab automation |
6.8% |
|
F. Hoffmann-La Roche Ltd. |
Switzerland |
RNA qPCR tools, diagnostics, omics platforms |
xx% |
|
Pacific Biosciences (PacBio) |
USA |
Long-read sequencing for transcript isoforms |
xx% |
|
Oxford Nanopore Technologies Ltd. |
UK |
Real-time, long-read sequencing |
xx% |
|
Bio-Rad Laboratories, Inc. |
USA |
ddPCR, RNA quantification and QC |
xx% |
|
NanoString Technologies Inc. |
USA |
nCounter, CosMx for spatial RNA profiling |
xx% |
|
Takara Bio Inc. |
Japan |
SMART-Seq, single-cell sequencing kits |
xx% |
|
Bruker Corporation |
USA |
Mass-spec-based RNA/protein studies, spatial omics |
xx% |
|
Eurofins Scientific SE |
Luxembourg |
Contract transcriptomics services |
xx% |
|
Genewiz (Azenta Life Sciences) |
USA |
RNA sequencing and transcriptomic analysis |
xx% |
|
Macrogen Inc. |
South Korea |
RNA-seq and gene expression services |
xx% |
|
GenScript Biotech Corp. |
USA/China |
RNA synthesis, sequencing, functional genomics |
xx% |
|
Becton, Dickinson and Company (BD) |
USA |
BD Rhapsody for single-cell transcriptomics |
xx% |
|
SciGenom Labs Pvt Ltd. |
India |
Clinical transcriptomics and RNA profiling |
xx% |
|
Australian Genome Research Facility (AGRF) |
Australia |
National transcriptomics and NGS service provider |
xx% |
|
Neoscience Sdn Bhd |
Malaysia |
Distributor for RNA analysis platforms in ASEAN |
xx% |
Below are the areas covered for each company in the transcriptomics market:
Recent Developments
- In January 2024, 10x Genomics launched the Xenium In Situ platform, a high-resolution spatial transcriptomics platform. The launch has contributed 9.2% of revenue growth, marking a strong place in spatial omics.
- In March 2024, Illumina released its Complete Long Read technology designed to complement short-read sequencing and resolve complex transcript isoforms and gene fusions. This product has enhanced transcript isoform identification accuracy by over 80%.
Author Credits:
- Report ID: 3935
- Published Date: Jun 25, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Transcriptomics Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
